News & Events about Harpoon Therapeutics Inc.
Globe Newswire
5 months ago
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor activity-secretase inhibitors increased the potency of HPN217 in vitro in multiple cell lines, supporting ...
Globe Newswire
5 months ago
Results support further investigation of two new ProTriTAC protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and integrin-beta6 (ITGB6)-expressing solid tumorsSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- ...
Gainers
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share.
read more...
Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? Thinking about buying stock in HTG Molecular Diagnostics, Harpoon Therapeutics, Acer Therapeutics, Aptevo Therapeutics, or Tonix Pharmaceuticals? PR...
Globe Newswire
9 months ago
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer ...